| Document |
Document Title |
|
WO/2017/160930A1 |
Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.
|
|
WO/2017/155910A1 |
A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclo...
|
|
WO/2017/155092A1 |
The present invention provides a composition for controlling a plant disease comprising a tetrazolinone compound represented by formula (1) wherein X1 represents a halogen atom etc., and X2 represents a C1-C3 alkyl group etc., and at lea...
|
|
WO/2017/154588A1 |
The present invention provides a novel method for producing a compound having an ester group, and a derivative produced using the compound as a synthesis intermediate. Also provided are a polymerizable composition containing a compound o...
|
|
WO/2017/149332A1 |
The subject of the present invention is the cocrystal form of (R)-2-(2-aminothiazol-4-yl)-4'- {2-[(2-hydroxy-2-phenyl)ethylamino]ethyl}acetamide (mirabegron) of formula (1) and halide salt of an alkaline earth metal or halide salt of a d...
|
|
WO/2017/147316A1 |
The invention provides synthetic processes and synthetic intermediates that can be used to prepare a compound of formula (I): or a salt thereof.
|
|
WO/2017/141049A1 |
Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, wherein W, X, Y, Z, x, R1, R2, R3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-...
|
|
WO/2017/137784A1 |
The object of the present invention relates to a method for the production of formula 1 (R)-2- (2-aminothiazole-4-yl)-4'-[2-[(2-hydroxy-2-phenyl)ethylamino
]ethyl]acetanilide (mirabegron) and formula 1c mirabegron monohydrochloride, as w...
|
|
WO/2017/134547A1 |
The present invention is directed to novel cytotoxic tubulysin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.
|
|
WO/2017/136375A1 |
This invention relates to deuterated forms of morpholinobenzo[d]thiazol-2-yl)-4-methylpiperidine-1-carboxa
mide compounds, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of ...
|
|
WO/2017/135786A1 |
The present invention relates to a novel amide compound usefully available for the prevention or treatment of a bone disease and the use thereof.
|
|
WO/2017/132158A1 |
The invention provides a crystalline form of the compound of formula (Ia), methods for making the crystalline form of the compound of formula (Ia), and therapeutic methods for the use of the crystal line form of the compound of formula (...
|
|
WO/2017/127627A1 |
The present invention relates to novel compounds that cross the blood-brain barrier and are effective inhibitors of neurological pathogens such as trypanosomes. The invention further relates to the use of these compounds for treating dis...
|
|
WO/2017/118641A1 |
The invention provides the L-valinate ester of a hydroxypropylthiazolidine carboxamide derivative of formula (I), (2S)-3-([1,1'-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1- phenylpropyl]-1,3-thiazolidine-2- carboxamide, as well as salts ...
|
|
WO/2017/118639A1 |
The invention provides pharmaceutical compositions comprising a compound of formula (I) or (II) and an additional therapeutic agent Also provided is the HCI salt and crystalline form of the compound of formula (I). The compounds inhibit ...
|
|
WO/2017/119570A1 |
The present invention relates to a novel thiazolidinedione derivative represented by chemical formulas 1a and 1b below, and to a pharmaceutical composition containing the same.
|
|
WO/2017/116646A1 |
Disclosed are compounds of Formulae 1, 1a, 1b and 2, INSERT FORMULAE 1, 1A, 1B AND 2 wherein R1, R1a, R1b, R2, R3 and R4 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formulae 1, 1a and 1b,...
|
|
WO/2017/108282A1 |
A compound of formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of a histone deacetylase, and as such is useful in terepy, e.g. in the treatment of autoimmune disorders, mental disorders, ne...
|
|
WO/2017/107972A1 |
Disclosed are crystalline forms 1, 2, and 3 of a selective S1P1 receptor agonist, namely Ponesimod, and a method for preparing the same. An X-ray powder diffraction pattern of the crystalline form 1 has characteristic peaks at 2 theta va...
|
|
WO/2017/108632A1 |
The invention relates to compounds acting as antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). Said compounds are useful in the treatment of diseases associated with activity...
|
|
WO/2017/106226A1 |
Disclosed are compounds of Formula A, or a salt thereof: Formula (A) wherein R1, R2, and E are defined herein, which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also describe...
|
|
WO/2017/098952A1 |
The present invention provides: a method for producing a polymerizable compound having a hydrazone moiety in which a substituent such as an alkyl group has been introduced on a nitrogen atom, and a benzothiazole moiety; and a composition...
|
|
WO/2017/097732A1 |
The invention relates to a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2017/098988A1 |
The present invention provides a polymerizable liquid crystal compound that is highly soluble in various kinds of solvent and that has reverse-wavelength dispersibility or low-wavelength dispersibility. The present invention also provide...
|
|
WO/2017/099237A1 |
A compound represented by formula (I) and having a property of modulating the activity of an androgen receptor, or a pharmaceutically acceptable salt of the compound. X represents S or O; Z represents (Ra)n-A-(CR13R14)0-1-(CR11R12)0-1-; ...
|
|
WO/2017/098391A1 |
The present invention relates to a process for preparation of stable Dasatinib base (I). The present invention further, relates to a process for preparation of amorphous Dasatinib base (I). Said stable Dasatinib base (I) may be useful in...
|
|
WO/2017/095929A1 |
Particular embodiments of the present invention include rubber articles manufactured at least in part from a rubber composition that is based upon a cross-linkable rubber composition, the cross-linkable rubber composition comprising, per...
|
|
WO/2017/095375A1 |
Particular embodiments of the present invention include rubber articles manufactured at least in part from a rubber composition that is based upon a cross -linkable rubber composition, the cross-linkable rubber composition comprising, pe...
|
|
WO/2017/090581A1 |
According to the present invention, a method for producing a carboxylic acid thioester is provided, which comprises reacting a compound represented by formula (I) with a carboxylic acid and a thiol in the presence of a catalyst comprisin...
|
|
WO/2017/088776A1 |
The present invention relates to a compound as shown by general formula (I), a racemate or optical isomer thereof, a pharmaceutically acceptable salt, solvate or hydrate thereof, a pharmaceutical composition comprising the compound, and ...
|
|
WO/2017/087818A1 |
Dual Src/p38 kinase inhibitor compounds and compositions comprising the same are disclosed. Methods of using the compounds in the treatment of hyperproliferative disease such as cancer are also disclosed.
|
|
WO/2017/083433A1 |
The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis in...
|
|
WO/2017/083859A1 |
The present invention relates to identification of inhibitors or antagonists of aminoarabinase glycosyltransferase (ArnT) and their use in compositions, methods of treatment or prevention of drug resistant gram negative infections, or in...
|
|
WO/2017/075694A1 |
The present invention relates to compounds of formula (I) wherein G1 to G8 are as defined herein. The compounds are PK inhibitors and as such represent a new approach to treating pathogenic infections, including multidrug resistant patho...
|
|
WO/2017/078927A1 |
Novel compounds having a formula (I), embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a s...
|
|
WO/2017/078403A1 |
The present disclosure relates to a plurality of host materials and an organic electroluminescent device comprising the same. By using a specific combination of a plurality of host compounds, it is possible to provide the organic electro...
|
|
WO/2017/078123A1 |
In a method for producing a dedimethoxybenzylation compound that removes a dimethoxybenzyl group, in the presence of an acid, from a compound, in which the dimethoxybenzyl group is bonded to a nitrogen atom, a dedimethoxybenzylation comp...
|
|
WO/2017/073942A1 |
The present disclosure relates to an electron buffering material, and an organic electroluminescent device comprising a first electrode, a second electrode facing the first electrode, a light-emitting layer between the first electrode an...
|
|
WO/2017/074053A1 |
The present application relates to a compound in chemical formula (1) and an organic light-emitting device comprising same.
|
|
WO/2017/071980A1 |
Provided is a method for producing flutemetamol including the steps of: reacting a precursor compound represented by a predetermined general formula with a radioactive fluoride to obtain a 18F labeling compound represented by a predeterm...
|
|
WO/2017/074052A1 |
The present application relates to an organic light-emitting device.
|
|
WO/2017/068860A1 |
The present invention provides a compound represented by general formula (I) and a polymerizable composition containing said compound. A polymerizable composition containing a compound represented by general formula (I), when used to pro...
|
|
WO/2017/065226A1 |
The present invention provides: a liquid crystal alignment agent that makes it possible to obtain a liquid crystal alignment film that has excellent rubbing resistance, fast reduction of accumulated charge and a high alignment regulating...
|
|
WO/2017/060914A2 |
Penicillamine and its derivatives, composition, methods of synthesizing and using the compound of formula 1 are disclosed. The compounds of formula 1 also comprises of salts, polymorphs, solvates and hydrates thereof. The compounds may b...
|
|
WO/2017/059614A1 |
The present invention discloses a preparation method of 2-mercaptobenzothiazole, in which an aniline process is employed to react under the action of a catalyst to prepare 2-mercaptobenzothiazole, and the catalyst comprises imidazolium i...
|
|
WO/2017/059303A1 |
Provided herein are vinylogous thioester compounds and methods for using the compounds.
|
|
WO/2017/056758A1 |
The present invention relates to a method for purifying pure thioflavin T, said method being provided with: a step for preparing a thioflavin T solution obtained by dissolving crude thioflavin T in a polar solvent; a step in which the th...
|
|
WO/2017/057344A1 |
The present invention pertains to a method for refining pure thioflavin T, the method being provided with a step for preparing a thioflavin T solution of crude thioflavin T dissolved in a polar solvent, and a step for performing liquid-l...
|
|
WO/2017/051353A1 |
Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of HIV; including the prevention of the p...
|
|
WO/2017/051761A1 |
The prodrug or a salt thereof according to the present invention is represented by the formula: D-X-L. (In the formula, D represents a useful compound and becomes D-X-H. X represents NR1, O, S, or Se. R1 represents a hydrogen atom, a sub...
|
